Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets

HERCULES, CA -- (Marketwired) -- 12/21/15 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity� system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.

Introduced to markets outside the U.S. in 2014, the TANGO infinity is next in the series following Bio-Rad's TANGO" optimo system and offers a high level of security with proven solid phase and hemagglutination testing methodologies, state-of-the art components, and sophisticated monitoring and control features.

"We are pleased to introduce the TANGO infinity to U.S. markets," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. "The system is designed to minimize manual steps to improve laboratory work flow and process samples with new security features. The availability of the TANGO infinity broadens our immunohematology product offering for U.S. markets."

Key Benefits of the TANGO infinity System

• 7-day on-board storage reduces manual workload in the lab
• High capacity to load reagents and samples, means less hands-on time
• Continuous monitoring of critical processes as well as reagent shelf-life
• QC management system ensures all lots and reagents are in control
• Optical liquid verification of sample and liquid reagent dispense volumes to ensure security and quality of testing
• Easy to learn and use
• Compact design offers small footprint, touch screen monitor, and user friendly interface

About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.

Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
Email Contact

Source: Bio-Rad Laboratories

You May Also Be Interested In

• Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
• Glow Announces Late Filing of Financial Statements
• Press Release for Early Warning Report Filed Pursuant to NI 62-103